Malarial Vaccines Market: Opportunity Analysis and Future Assessment 2020-2028

Malaria is a life-threatening disease in many regions that are tropical and subtropical in nature, which further gives the parasite to grow in an abundant population. There are around 100 countries that are in the effect of malaria currently, which most of the countries are in the African region and risk increase by the increase in traveling of the tourists in such countries. Travelers moving in the countries with ongoing local malaria transmission coming from regions of no transmission are comparatively at higher risk of malaria and consequences related due to the lack of immunity. Furthermore, the migrants moving from countries with malarial transmission staying in the malaria-free regions and returning to their residential countries to visit their relatives are similarly at significant risk because of waning or absent immunity.

Malaria is caused by the parasite such as Plasmodium. Human malaria is caused by four different species of Plasmodium: P. falciparum, P. malariae P. ovale and P. vivax. According to the WHO, in 2015, around 214 Mn cases of malaria were found globally that initiated the positive thought process of various governments to take a check on the endemic in the respective regions. Though, there was around 37% decrease in the malarial incidence globally between 2000 and 2015 with 60% deaths due to malaria in the same period of time. The increase in the prevalence of malaria in the emerging economies is expected to support the malarial vaccines market in the near future. Vaccines that can act as the prophylactic agents in malaria are to be launched in 2018 by the effective collaboration of PATH/MVI (Path Malarial vaccine initiative) and GSK that began in 2001 whose first candidate is named as RTS,S/AS01 or Mosquirix™.

The global malarial vaccines market in 2020 is estimated for more than US$ 22.7 Mn and expected to reach a value of US$ 237.2 Mn by 2028 with a significant CAGR of 34.1%.

Global malarial vaccines market is mainly dominated by

• GlaxoSmithKline plc

• Sanaria Inc.

• Nobelpharma Co., Ltd.

• Sumaya Biotech

• GenVec, Inc.

• GeoVax Labs, Inc.

The global malarial vaccines market is segmented on the basis of agent type, vaccine type, distribution channel, and region

On the basis of the agent type, the global malarial vaccines market can be segmented into:

• Plasmodium Falciparum

• Plasmodium Vivax

• Plasmodium Malariae

• Plasmodium Ovale

On the basis of vaccines type, the global malarial vaccines market can be segmented into:

• Pre-Erythrocytic Vaccine

• Erythrocytic Vaccine

• Multi-Antigen Vaccine

On the basis of distribution channel, the global malarial vaccines market can be segmented into

• Hospitals

• Community Centers

• Clinics

The global malarial vaccines market is expected to increase at a significant CAGR over the forecast period owing to the increasing prevalence and government initiatives for proper relief across the healthcare receivers.

Increasing expenditure in vaccine development in the industry is also one of the major factors, which is expected to increase the demand for the malarial vaccines market globally over the forecast period. With the increase in awareness for malarial vaccines by the various communities and the government.

On the basis of region, the global malarial vaccines market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. Africa malarial vaccines market is expected to be the most dominating market throughout the forecast period. The high prevalence of the disease is expected to be one of the main factors to support the increase in the malarial vaccines market over the forecast period.

1.    Global Malarial Vaccines Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Malarial Vaccines Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Malarial Vaccines Market Snapshot

2.4.    Global Malarial Vaccines Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Malarial Vaccines Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Malarial Vaccines Market, By Agent Type

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Agent Type

3.1.2.    BPS Analysis, By Agent Type

3.2.    Market Revenue (US$Mn) Forecast, By Agent Type

3.2.1.    Plasmodium Falciparum

3.2.2.    Plasmodium Vivax

3.2.3.    Plasmodium Malariae

3.2.4.    Plasmodium Ovale

3.3.     Global Malarial Vaccines Market Attractiveness Index, By Agent Type

4.    Global Malarial Vaccines Market, By Vaccines Type

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Vaccines Type

4.1.2.    BPS Analysis, By Vaccines Type

4.2.    Market Revenue (US$Mn) Forecast, By Vaccines Type

4.2.1.    Pre-Erythrocytic Vaccine

4.2.2.    Erythrocytic Vaccine

4.2.3.    Multi-Antigen Vaccine

4.3.     Global Malarial Vaccines Market Attractiveness Index, By Vaccines Type

5.    Global Malarial Vaccines Market, By Distribution Channel

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Distribution Channel

5.1.2.    BPS Analysis, By Distribution Channel

5.2.    Market Revenue (US$Mn) Forecast, By Distribution Channel

5.2.1.    Hospitals

5.2.2.    Community Centers

5.2.3.    Clinics

5.3.     Global Malarial Vaccines Market Attractiveness Index, By Distribution Channel

6.    Global Malarial Vaccines Market, By Region

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Region

6.1.2.    BPS Analysis, By Region

6.2.    Market Revenue (US$Mn) Forecast, By Region

6.2.1.    North America

6.2.2.    Latin America

6.2.3.    Europe

6.2.4.    Asia Pacific

6.2.5.    Middle East

6.2.6.    Africa

6.3.    Global Malarial Vaccines Market Attractiveness Index, By Region

7.    North America Malarial Vaccines Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market Revenue (US$Mn) Forecast, By Country

7.2.1.    U.S. Malarial Vaccines Market

7.2.2.    Canada Malarial Vaccines Market

7.3.    North America Malarial Vaccines Market, By Agent Type

7.3.1.    Plasmodium Falciparum

7.3.2.    Plasmodium Vivax

7.3.3.    Plasmodium Malariae

7.3.4.    Plasmodium Ovale

7.4.    North America Malarial Vaccines Market, By Vaccines Type

7.4.1.    Pre-Erythrocytic Vaccine

7.4.2.    Erythrocytic Vaccine

7.4.3.    Multi-Antigen Vaccine

7.5.    North America Malarial Vaccines Market, By Distribution Channel

7.5.1.    Hospitals

7.5.2.    Community Centers

7.5.3.    Clinics

7.6.    North America Malarial Vaccines Market Attractiveness Index

7.6.1.    By Country

7.6.2.    By Agent Type

7.6.3.    By Vaccines Type

7.6.4.    By Distribution Channel

8.    Latin America Malarial Vaccines Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    Brazil Malarial Vaccines Market

8.2.2.    Mexico Malarial Vaccines Market

8.2.3.    Argentina Malarial Vaccines Market

8.2.4.    Rest of Latin America Malarial Vaccines Market

8.3.    Latin America Malarial Vaccines Market, By Agent Type

8.3.1.    Plasmodium Falciparum

8.3.2.    Plasmodium Vivax

8.3.3.    Plasmodium Malariae

8.3.4.    Plasmodium Ovale

8.4.    Latin America Malarial Vaccines Market, By Vaccines Type

8.4.1.    Pre-Erythrocytic Vaccine

8.4.2.    Erythrocytic Vaccine

8.4.3.    Multi-Antigen Vaccine

8.5.    Latin America Malarial Vaccines Market, By Distribution Channel

8.5.1.    Hospitals

8.5.2.    Community Centers

8.5.3.    Clinics

8.6.    Latin America Malarial Vaccines Market Attractiveness Index

8.6.1.    By Country

8.6.2.    By Agent Type

8.6.3.    By Vaccines Type

8.6.4.    By Distribution Channel

9.    Europe Malarial Vaccines Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    U.K. Malarial Vaccines Market

9.2.2.    Germany Malarial Vaccines Market

9.2.3.    Italy Malarial Vaccines Market

9.2.4.    France Malarial Vaccines Market

9.2.5.    Spain Malarial Vaccines Market

9.2.6.    Russia Malarial Vaccines Market

9.2.7.    Poland Malarial Vaccines Market

9.2.8.    BENELUX Malarial Vaccines Market

9.2.9.    NORDIC Malarial Vaccines Market

9.2.10.    Rest of Europe Malarial Vaccines Market

9.3.    Europe Malarial Vaccines Market, By Agent Type

9.3.1.    Plasmodium Falciparum

9.3.2.    Plasmodium Vivax

9.3.3.    Plasmodium Malariae

9.3.4.    Plasmodium Ovale

9.4.    Europe Malarial Vaccines Market, By Vaccines Type

9.4.1.    Pre-Erythrocytic Vaccine

9.4.2.    Erythrocytic Vaccine

9.4.3.    Multi-Antigen Vaccine

9.5.    Europe Malarial Vaccines Market, By Distribution Channel

9.5.1.    Hospitals

9.5.2.    Community Centers

9.5.3.    Clinics

9.6.    Europe Malarial Vaccines Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Agent Type

9.6.3.    By Vaccines Type

9.6.4.    By Distribution Channel

10.    Asia Pacific Malarial Vaccines Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    China Malarial Vaccines Market

10.2.2.    India Malarial Vaccines Market

10.2.3.    Japan Malarial Vaccines Market

10.2.4.    Australia and New Zealand Malarial Vaccines Market

10.2.5.    South Korea Malarial Vaccines Market

10.2.6.    ASEAN Malarial Vaccines Market

10.2.7.    Rest of Asia Pacific Malarial Vaccines Market

10.3.    Asia Pacific Malarial Vaccines Market, By Agent Type

10.3.1.    Plasmodium Falciparum

10.3.2.    Plasmodium Vivax

10.3.3.    Plasmodium Malariae

10.3.4.    Plasmodium Ovale

10.4.    Asia Pacific Malarial Vaccines Market, By Vaccines Type

10.4.1.    Pre-Erythrocytic Vaccine

10.4.2.    Erythrocytic Vaccine

10.4.3.    Multi-Antigen Vaccine

10.5.    Asia Pacific Malarial Vaccines Market, By Distribution Channel

10.5.1.    Hospitals

10.5.2.    Community Centers

10.5.3.    Clinics

10.6.    Asia Pacific Malarial Vaccines Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Agent Type

10.6.3.    By Vaccines Type

10.6.4.    By Distribution Channel

11.    Middle East Malarial Vaccines Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    GCC Countries Malarial Vaccines Market

11.2.2.    Israel Malarial Vaccines Market

11.2.3.    Oman Malarial Vaccines Market

11.2.4.    Rest of Middle East Malarial Vaccines Market

11.3.    Middle East Malarial Vaccines Market, By Agent Type

11.3.1.    Plasmodium Falciparum

11.3.2.    Plasmodium Vivax

11.3.3.    Plasmodium Malariae

11.3.4.    Plasmodium Ovale

11.4.    Middle East Malarial Vaccines Market, By Vaccines Type

11.4.1.    Pre-Erythrocytic Vaccine

11.4.2.    Erythrocytic Vaccine

11.4.3.    Multi-Antigen Vaccine

11.5.    Middle East Malarial Vaccines Market, By Distribution Channel

11.5.1.    Hospitals

11.5.2.    Community Centers

11.5.3.    Clinics

11.6.    Middle East Malarial Vaccines Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Agent Type

11.6.3.    By Vaccines Type

11.6.4.    By Distribution Channel

12.    Africa Malarial Vaccines Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    South Africa Malarial Vaccines Market

12.2.2.    Egypt Malarial Vaccines Market

12.2.3.    North Africa Malarial Vaccines Market

12.2.4.    Rest of Africa Malarial Vaccines Market

12.3.    Africa Malarial Vaccines Market, By Agent Type

12.3.1.    Plasmodium Falciparum

12.3.2.    Plasmodium Vivax

12.3.3.    Plasmodium Malariae

12.3.4.    Plasmodium Ovale

12.4.    Africa Malarial Vaccines Market, By Vaccines Type

12.4.1.    Pre-Erythrocytic Vaccine

12.4.2.    Erythrocytic Vaccine

12.4.3.    Multi-Antigen Vaccine

12.5.    Africa Malarial Vaccines Market, By Distribution Channel

12.5.1.    Hospitals

12.5.2.    Community Centers

12.5.3.    Clinics

12.6.    Africa Malarial Vaccines Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Agent Type

12.6.3.    By Vaccines Type

12.6.4.    By Distribution Channel

13.    Recommendation

13.1.    Market Strategy

14.    Competitive Landscape

14.1.    Competition Dashboard

14.2.    List and Company Overview of Global Key Players

14.3.    Company Profiles

14.3.1.    GlaxoSmithKline plc 

14.3.1.1.    Company Overview

14.3.1.2.    Financial Overview

14.3.1.3.    Product Portfolio

14.3.1.4.    Key Developments

14.3.1.5.    Business Strategies

14.3.2.    Sanaria Inc.

14.3.3.    Nobelpharma Co., Ltd.

14.3.4.    Sumaya Biotech

14.3.5.    GenVec, Inc.

14.3.6.    GeoVax Labs, Inc.

15.    Acronyms